jobs.jnj.com/en/jobs/
Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Our Businesses
Explore more Johnson & Johnson sites:
Switzerland
Our Company

Our Statement on the Los Angeles Talc Verdict

Today's Top Reads Close
Share expand

“Ovarian cancer is a devastating diagnosis and we deeply sympathize with the women and families impacted by this disease. We will appeal today’s verdict because we are guided by the science, which supports the safety of Johnson’s Baby Powder. In April, the National Cancer Institute’s Physician Data Query Editorial Board wrote, ‘The weight of evidence does not support an association between perineal talc exposure and an increased risk of ovarian cancer.’ We are preparing for additional trials in the U.S. and we will continue to defend the safety of Johnson’s Baby Powder.” - Carol Goodrich, Global Media Relations, Johnson & Johnson Consumer, Inc.

For more information, please also see: 5 Important Facts About the Safety of Talc

Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue